ReferenceID 6281
Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
J Transl Med
Background: Breast cancer (BC) is one of the most common malignant tumors with the highest mortality in the world. Modern pharmacological studies have shown that Syringin has an inhibitory effect on many tumors, but its
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 6281
- Evidence Id
- 22871
- Core Evidence Id
- 22871
- Source Reference Id
- 5837
- Herb2 Reference Id
- HBREF006634
- Subject Paper Key
- HBIN045298_35794555
- Pubmed Id
- 35794555
- Doi
- 10.1186/s12967-022-03504-6
- Paper Title
- Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
- Paper Abstract
- Background: Breast cancer (BC) is one of the most common malignant tumors with the highest mortality in the world. Modern pharmacological studies have shown that Syringin has an inhibitory effect on many tumors, but its anti-BC efficacy and mechanism are still unclear. Methods: First, Syringin was isolated from Acanthopanax senticosus (Rupr. & Maxim.) Harms (ASH) by systematic solvent extraction and silica gel chromatography column. The plant name is composed of genus epithet, species additive words and the persons' name who give its name. Then, the hub targets of Syringin against BC were revealed by bioinformatics. To provide a more experimental basis for later research, the hub genes which could be candidate biomarkers of BC and a ceRNA network related to them were obtained. And the potential mechanism of Syringin against BC was proved in vitro experiments. Results: Syringin was obtained by liquid chromatography-mass spectrometry (LC-MS), nuclear magnetic resonance (NMR), and high-performance liquid chromatography (HPLC). Bioinformatics results showed that MAP2K1, PIK3CA, HRAS, EGFR, Caspase3, and PTGS2 were the hub targets of Syringin against BC. And PIK3CA and HRAS were related to the survival and prognosis of BC patients, the PIK3CA-hsa-mir-139-5p-LINC01278 and PIK3CA-hsa-mir-375 pathways might be closely related to the mechanism of Syringin against BC. In vitro experiments confirmed that Syringin inhibited the proliferation and migration and promoted apoptosis of BC cells through the above hub targets. Conclusions: Syringin against BC via PI3K-AKT-PTGS2 and EGFR-RAS-RAF-MEK-ERK pathways, and PIK3CA and HRAS are hub genes for adjuvant treatment of BC.
- Journal
- J Transl Med
- Publish Year
- 2022
- Experiment Subject
- patient; bc cells; person
- Experiment Type
- Cell Experiment
- Phenotype Related
- Malignant Tumors; Breast Cancer; Tumors
- Paper Title Cn
- Paper Title En
- Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
- Bilingual Status
- semi_complete